Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.78% is 63% below its 5-year average of -23.19%, near the low end of its 5-year range (-54.44%–19.17%).
51.42% below its 12-month average of -24.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.34%.
RETURN ON ASSETS (ROA)
-37.78%
RETURN ON ASSETS (ROA) AVG TTM
-24.95%
RETURN ON ASSETS (ROA) AVG 3Y
-12.79%
RETURN ON ASSETS (ROA) AVG 5Y
-23.19%
RETURN ON ASSETS (ROA) AVG 10Y
-29.12%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-51.42%
CURRENT VS 3Y AVG
-195.39%
CURRENT VS 5Y AVG
-62.92%
CURRENT VS 10Y AVG
-29.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-17.09%
vs the sector median at left
Zymeworks Inc.
Market Cap
$1.89B
Return on Assets (ROA)
-37.78%
TTM Avg
-24.95%
3Y Avg
-12.79%
5Y Avg
-23.19%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.89B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.87B
Return on Assets (ROA)
-15.46%
TTM Avg
-32.65%
3Y Avg
-30.38%
5Y Avg
-46.54%
Market Cap
$1.86B
Return on Assets (ROA)
-25.92%
TTM Avg
12.70%
3Y Avg
-8.51%
5Y Avg
-21.36%
Market Cap
$1.92B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.85B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$1.94B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$1.84B
Return on Assets (ROA)
-24.34%
TTM Avg
-44.90%
3Y Avg
-10.89%
5Y Avg
-12.22%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zymeworks Inc. (ZYME) | $1.89B | -37.78% | -24.95% | -12.79% | -23.19% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -37.11% | 4.34% | -11.90% | 4.27% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | -15.46% | -32.65% | -30.38% | -46.54% |
| Novavax, Inc. (NVAX)vs › | $1.86B | -25.92% | 12.70% | -8.51% | -21.36% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -11.05% | -19.34% | -25.88% | -26.23% |
| Immunome, Inc. (IMNM)vs › | $1.85B | -44.98% | -76.52% | -94.59% | -76.85% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | -52.34% | -54.87% | -41.09% | -94.89% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -24.34% | -44.90% | -10.89% | -12.22% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 1.78% | 2.10% | 3.84% | 3.40% |
ROA
-37.8%
ROE
-186.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -23.41% |
| 2024-12-31 | -26.49% |
| 2023-12-31 | -20.43% |
| 2022-12-31 | 19.17% |
| 2021-12-31 | -54.44% |
| 2020-12-31 | -33.54% |
| 2019-12-31 | -39.50% |
| 2018-12-31 | -14.96% |
| 2017-12-31 | -7.89% |
| 2016-12-31 | -35.97% |
| 2015-12-31 | -82.81% |
| 2014-12-31 | -25.54% |
